Optic neuritis remains a common diagnosis with controver-
A cute optic neuritis is a common clinical dilemma and there remain many controversial aspects to the appropriate management and treatment of this condition. It has been almost 2 decades since the initial results from the Optic Neuritis Treatment Trial (ONTT) were published, and since then the findings from this landmark trial have been cited over 1000 times. [1] [2] [3] [4] [5] [6] [7] In this review on management dilemmas in the treatment of acute optic neuritis, our goal is not only to revisit controversies stemming from the ONTT but also to focus on several newer topics of interest surrounding 1) the initial treatment of typical optic neuritis, 2) possible new emerging treatments for typical optic neuritis, 3) diagnostic evaluation in atypical optic neuritis, and 4) the determination of which patients may benefit from institution of long-term immunosuppressive therapy after typical acute optic neuritis.
STEROIDS IN TYPICAL OPTIC NEURITIS-TREATING THE PATIENT OR THE PHYSICIAN?
Patients with typical optic neuritis can usually expect to have a rapid, significant recovery of visual acuity in the weeks to months after their initial symptoms. 5, 7, 8 Overall, approximately 95% of all patients enrolled in the ONTT at 1-year follow-up had a visual acuity better than 20/40, and over 70% had a visual acuity of 20/20 or better. 9 Over the 15-year follow-up period, only a few patients that remained in the study had recurrent optic neuritis or worsening visual deficits, and 90% of patients still had a visual acuity better than 20/40. 5 The patient population studied in this trial was representative of typical optic neuritis. Recent serum testing of available stored samples from the trial (40% of the total study population) showed that no patients harbored the aquaporin-4 (AQP4) antibody and only 3 patients tested positive for the myelin oligodendrocyte glycoprotein (MOG) antibody. 10 Even though visual acuity improves substantially for the vast majority of patients with typical acute optic neuritis, many patients have permanent deficits demonstrated by more sensitive measures of visual outcome, including low-contrast visual acuity, contrast sensitivity, color vision, and visual fields. In fact, up to 59% of patients with typical courses of optic neuritis report visual impairment at 1 year. 11 The more sensitive indicators of long-term visual loss are closely linked to quality of life, despite good improvement of high-contrast visual acuity. [12] [13] [14] Patients with more severe vision loss at onset of symptoms are more likely to have lasting visual impairment. 7 In addition, patients who were later diagnosed with clinically definite multiple sclerosis (MS) were more likely to have permanent visual deficits compared with patients who did not develop MS. 5, 15 Because even the seemingly "benign" course of optic neuritis often leads to persistent disability, it remains an important question whether patients may benefit from treatment at the time of diagnosis that improves the long-term visual prognosis. The best data addressing this question remains that from the ONTT, which showed improvement in color vision and contrast sensitivity at 6 months in patients who received high dose intravenous (IV) steroids compared with patients who received lower dose oral prednisone or oral placebo. 7 However, the study showed no differences in any functional outcomes between these treatment groups at 1 year. 9 The authors reported that high dose intravenous steroids hastened visual recovery at 15 days, although this difference in rate of improvement was not a prespecified endpoint of the trial. 7 Subsequent analyses suggested that the group treated with oral prednisone had a higher rate of recurrent optic neuritis at 24-month follow-up (although this finding also was not a prespecified primary outcome, and the result has not been replicated in any other trial since). In addition, the study suggested that high dose IV steroids reduce the risk of developing clinically definite MS over the subsequent 2 years, but no effect was seen at 5-year follow-up. Some have criticized this finding, suggesting that observation can be attributed to post-hoc recoding of baseline MS diagnoses in the original cohort. [16] [17] [18] In addition to the limitations in the reported data, other criticisms of the methodology of the ONTT include the lack of an IV placebo group, particularly as most of the results pertain to the efficacy of IV steroids.
A 2015 updated Cochrane review that looked at data from the ONTT and 5 additional clinical trials analyzing steroid treatment for acute optic neuritis (conducted in Denmark, Germany, India, Japan, and the United Kingdom) concluded that there was no available evidence demonstrating beneficial effect from treatment of typical optic neuritis with oral or intravenous steroids with respect to the outcome of visual acuity. 19 Although group analyses of clinical trial data for typical optic neuritis does not show a long-term benefit of treatment with IV or oral steroids, it remains unclear whether there are particular subsets of patients that might benefit or how those subgroups could be predicted. In contrast, certain atypical cases of optic neuritis may substantially benefit from steroid and other immunosuppressive treatment (this situation is discussed later).
Because the findings of the ONTT remain challenging to interpret, a range of justifiable treatment approaches are common in practice. Practicing neurologists and ophthalmologists often either prescribe IV steroids or withhold treatment completely. In our experience in a high volume clinical center in the United States, neurologists are much more likely than ophthalmologists to prescribe high dose intravenous steroids. This is in part due to neurologists being more comfortable prescribing intravenous steroids and weighing the benefit of faster visual recovery as adequate justification for treatment. On the other hand, ophthalmologists more commonly do not prescribe intravenous steroids, partly in recognition of the known (and sometimes severe) complications of high dose steroid therapy. Our experience is borne out by international survey data. The Optic Neuritis Survey Group has published several papers detailing this lack of consensus within the international community of ophthalmologists and neurologists. [20] [21] [22] [23] A survey of neurologists and ophthalmologists in the United States, Canada, Australia/New Zealand, Denmark, France, and Thailand showed that neurologists were more likely than ophthalmologists to treat acute optic neuritis with high dose intravenous steroids (at the far ends of the spectrum, approximately 97% of neurologists in France prescribe IV steroids whereas 65% of ophthalmologists in Denmark do not treat with any steroids). 20 In addition to illuminating the range of current practices among physicians, the Optic Neuritis Survey Group has also highlighted some persistent misinterpretation of the literature. For example, although the majority of neurologists surveyed in the southeastern United States indicated that they were familiar with the ONTT, 72% reported believing that intravenous steroids were shown to improve long-term visual outcome. 20 Although the ONTT was a landmark study that shed some light on the effects of corticosteroid treatment of acute optic neuritis, we still clearly have a need for more definitive data supporting treatments for optic neuritis that improve its long-term prognosis.
ACUTE OPTIC NEURITIS TREATMENT-ARE NEUROPROTECTIVE DRUGS AND ALTERNATIVE IMMUNOTHERAPIES READY FOR PRIME TIME?
Multiple trials have assessed a variety of treatments other than corticosteroids to improve visual outcome after acute optic neuritis. An important point to note is that most of these recent trials are relatively small studies probing possible efficacy. For this reason, the studies are not powered to detect an effect on visual function directly, and the primary outcomes of these trials generally are structural measures [ie, measurement of retinal nerve fiber layer (RNFL) by optical coherence tomography (OCT)] or functional surrogate measures [ie, P100 latency on visual evoked potentials (VEP)]. Some of these studies show promising candidates, and future studies will hopefully define their therapeutic role.
Studies in animal models have shown that neurodegeneration in the form of permanent axonal loss after an attack of acute inflammatory demyelination may in part be mediated by dysregulation of small molecules called neurotrophins, which normally promote axonal growth and plasticity via receptor tyrosine kinases. 24, 25 Because erythropoietin is known to exhibit neurotrophinlike properties, it was evaluated in patients with acute optic neuritis in a randomized, placebo-controlled trial. The trial did show a decrease in RNFL thinning in patients treated with erythropoietin, meeting its primary outcome, but the treatment effect is difficult to interpret because it was a small study with significant variance among the baseline characteristics of the placebo and treatment arms. 24 Further work is needed to draw definitive conclusions about the utility of erythropoietin in treating acute optic neuritis.
Neuronal energy failure is another important proposed mechanism that may contribute to long-term axonal damage after acute relapses. Animal models have shown that phenytoin, a sodium channel inhibitor, may have neuroprotective effects by limiting intracellular accumulation of sodium ions. 26 A randomized, placebo-controlled trial showed that administration of phenytoin led to reduction in RNFL thinning 6 months after acute optic neuritis. 26 Further studies are needed to determine whether phenytoin or other treatments targeting ion channels effectively improve long-term functional visual outcomes.
Intravenous immunoglobulin (IVIg) has been studied as an alternative immunotherapy to corticosteroids in the treatment of acute optic neuritis but has not shown significant efficacy. One double-blind, randomized, placebo-controlled trial evaluating IVIg found no difference in visual acuity, color vision, contrast sensitivity, or VEP measures 6 months after acute optic neuritis. 27 A separate trial comparing IVIg with placebo in patients with chronic visual deficits after prior optic neuritis also did not show any benefit. 28 More recent studies have focused on novel mechanisms potentially supporting remyelination. One potential therapeutic target is the leucine-rich repeat and immunoglobulin domain-containing neurite outgrowth inhibitor receptor-interacting protein-1 (LINGO-1), which is an inhibitor of oligodendrocyte differentiation and remyelination. 29 Animal models have shown that blocking LINGO-1 may improve remyelination and have additional neuroprotective effects. The first randomized, double-blind, placebo-controlled phase 2 trial in humans administering a human monoclonal antibody at the time of acute optic neuritis did not meet its primary endpoint, (assessment of P100 latency on full-field VEP) in an intention-to-treat analysis, although a perprotocol analysis did show a statistically significant difference. 29 This trial was limited by a delayed enrollment (average 24 days) after initial symptoms. Although the primary endpoint was negative, there were positive signals that LINGO-1 blockade might be beneficial.
An additional double-blind, randomized, placebo-controlled, crossover trial evaluated clemastine fumarate for the treatment of chronic optic neuropathy. 30 Clemastine is a molecule that has been shown to stimulate differentiation of oligodendrocyte precursor cells in animal models and in vitro human cell culture. The results of this trial showed an improvement in optic nerve conduction assessed by the VEP P100 latency. However, patients with a history of optic neuritis within the past 6 months were excluded, and the average time elapsed until trial enrollment for patients with a history of optic neuritis was 4.3 years. 30 Future studies are necessary to further assess efficacy in patients with acute optic neuritis.
SEVERE AND/OR ATYPICAL OPTIC NEURITIS-DOES SOMETHING MORE SINISTER LURK UNDERNEATH?
In contrast to patients who present with mild optic neuritis who had high rates of visual recovery, a significant percentage of patients presenting with severe vision loss (counting fingers or light perception only) often have poor visual recovery. Within this subset of patients in the ONTT, 15% had poor long-term visual outcomes with high-contrast visual acuity worse than 20/100, and 10% of patients had visual acuity worse than 20/400. 5 Several studies have reliably shown that patients with a severe demyelinating syndrome, including optic neuritis, who do not respond to high dose steroids are likely to benefit from more potent immunotherapy such as plasma exchange. [31] [32] [33] [34] These studies include many patients with non-MS phenotypes (such as recurrent or bilateral optic neuritis related to neuromyelitis optica), but for the majority the severe optic neuritis is still idiopathic or a manifestation of MS. Knowing that there is a subset of patients in whom the long-term recovery can be quite limited, it is critical to ask whether there is an atypical optic neuritis phenotype that the clinician must recognize at onset and treat more aggressively to avoid a poor outcome.
Further investigation since the era of the ONTT has identified neuromyelitis optica spectrum disorder (NMOSD) as an AQP4 antibody-associated disorder with distinct pathophysiology, outcomes, and optimal treatment protocols from MS. In contrast to patients with idiopathic or MS-related optic neuritis, patients with NMOSD often have severe, permanent vision loss. Eighty percent of patients with NMOSD present with severe vision loss (visual acuity worse than 20/200) and many have poor recovery with severe, permanent deficits. These patients typically show a pattern of contrast enhancement on magnetic resonance imaging (MRI) that is greater than half the length of the optic nerve or involves the optic chiasm. In addition, they lack MRI findings typical for MS, can have a neutrophilic pleocytosis in the cerebrospinal fluid (CSF), and do not have oligoclonal bands in the CSF. 35 As will be discussed below, screening for and identifying these patients early is critical because steroid treatment may not be adequate; these patients often require more potent immunotherapy such as plasma exchange and ongoing immunosuppression to achieve optimal outcomes.
Screening for atypical or alternative causes of optic neuritis is particularly important in populations with relatively low prevalence of multiple sclerosis. Although rates of MS have increased in recent years (particularly in Japan), East Asia has the lowest rates of MS prevalence in the world.
36-39 Additionally, NMOSD seems to have important ethnic variations in its prevalence. 40 The combination of lower rates of MS and higher rates of NMOSD leads to a much higher proportion of NMOSD in patients presenting with demyelinating syndromes including optic neuritis. For example, NMOSD comprises 39.5% of acquired demyelinating disease in Thailand compared with only 1-2% in the United States. 41 We routinely screen for AQP4 antibodies in patients with severe vision loss, chiasmal or bilateral involvement, markedly inflammatory CSF profile, ethnicities in which there is a greater prevalence of NMOSD, or if there are other clinical features suggestive of NMOSD such as longitudinally extensive transverse myelitis. In these cases, we often start treatment with high dose corticosteroids, but if there is high enough pretest probability for NMOSD in patients with the above features, we commonly treat with adjuvant plasma exchange at initial presentation before receiving confirmatory AQP4 antibody laboratory results. A recent retrospective review showed that early, rapid escalation of therapy from high dose steroids to plasma exchange resulted in increased rates of recovery for patients with optic neuritis secondary to NMOSD. 42 It is important to identify this population early both because these patients can be refractory to corticosteroid monotherapy and require additional, more aggressive acute treatment but also because NMOSD can be exacerbated by administering particular MS medications such as beta interferons and natalizumab. 35 Many patients with a suspected NMOSD phenotype will have negative testing for the AQP4 antibody. Recent studies have shown that up to 20% of these patients will test positive for the MOG antibody. 43 These antibodies are readily identified on cellbased assay with high sensitivity and specificity. 44 The features of anti-MOG-related optic neuritis are still being characterized, and there has been some discrepancy in the literature regarding the clinical phenotype. Initial smaller studies found that these patients had slightly different characteristics than the overall NMOSD population, suggesting that they were more likely to be men, present with bilateral optic neuritis, and have a monophasic illness with better prognosis. 45, 46 However, several other studies have shown that patients with MOG antibodies do not necessarily have a more benign course. Two cohorts out of Germany and Spain of approximately 50 adult patients with MOG antibodies and acute demyelinating syndromes demonstrated that adults with MOG antibodies were likely to have optic neuritis with a recurrent disease course (71% and 80%) and high rates of NMOSD (25% and 32%). 47, 48 It remains unclear whether patients with anti-MOG antibodies can have a neurological syndrome that resembles MS; one study found that 25% had lesions on MRI suggestive of MS whereas another study found these changes in just 2%. 47, 48 Overall, anti-MOG antibody-related optic neuritis seems to present with more severe visual loss than either idiopathic or MS-related optic neuritis. These patients are also possibly at higher risk of relapse. 49 The severity of MOG-related optic neuritis can resemble NMOSD, but the long-term clinical outcome seems to be more favorable.
Even though there are conflicting data regarding long-term visual prognosis in patients with optic neuritis associated with anti-MOG antibodies, some studies have demonstrated objective markers of more severe injury. A cohort of patients with anti-MOG antibodies with a history of optic neuritis, with or without an MSlike illness, showed RNFL thinning on OCT that was more severe than both patients with a history of idiopathic optic neuritis and those with a history of AQP4-related optic neuritis. 50 These patients also had high rates of RNFL thinning in eyes without a clinical history of optic neuritis along with high rates of microcystic macular edema (24%). 50 One caveat in this cohort is that patients with anti-MOG antibodies had higher rates of optic neuritis than their counterparts. A different study out of Japan saw conflicting results, with retinal thinning on OCT actually being worse in the MS and NMO cohorts compared with the anti-MOG cohort. 51 We do not yet have any clinical trials evaluating treatment for these patients. However, clinical observation suggests that these patients are highly steroid responsive and may require a longer steroid taper, often with "steroid-sparing" adjuvant immunotherapy (ie, mycophenolate, azathioprine) after initial treatment. 52, 53 Thus, we routinely send testing for anti-MOG in patients with severe vision loss or bilateral involvement, as seropositive patients seem to benefit from a prolonged steroid course but can be spared the toxicities associated with more potent immunotherapies.
In contrast to adult patients with optic neuritis, children are more likely to have features that we would call atypical in the adult population. Vision loss in pediatric optic neuritis is often more severe; 70% of patients will have a visual acuity of worse than 20/200 at onset. 54, 55 In addition, 70% of children under the age of 10 will have bilateral involvement. However, similar to adults, almost all patients will have significant improvement in visual acuity, whereas more sensitive measures such as color vision and low-contrast vision remain impaired, corresponding to permanent structural and functional alterations of nerve fiber thickness on OCT and VEP latency. 56, 57 The most recent work studying pediatric patients with MOG antibodies was done by a large multinational cohort in Europe. 58 They made several important clinical observations. The prevalence of MOG antibodies was quite common, seen in approximately one third in their cohort of children presenting with acute demyelinating syndromes. In addition, there were 2 subgroups of presentation. Younger children, median age of 4.5 years, were more likely to present with acute disseminated encephalomyelitis and have transient presence of antibodies. Older children, median age 8 years, were more likely to be female and have a recurrent demyelinating syndrome, including recurrent optic neuritis. These patients were more likely to have persistently elevated titers of MOG antibodies. 58 Further work in a prospective study showed that standard MS disease-modifying therapy did not result in clinical improvement for patients with an acquired demyelinating syndrome associated with anti-MOG antibodies (including optic neuritis). 59 However, these patients did respond to a host of other immunotherapies, including azathioprine, rituximab, and IVIg, which seemed to be the most efficacious. 59 This responsiveness to IVIg in particular stands in contrast to the prior clinical trials showing poor efficacy in adult optic neuritis.
OPTIC NEURITIS AS A CLINICALLY ISOLATED SYNDROME-WHEN TO START MS DISEASE-MODIFYING TREATMENT?
Optic neuritis can be idiopathic but is often associated with MS. Worldwide, the incidence of MS is approximately 1-6 persons per 100,000 per year, and optic neuritis is the presenting feature in approximately 25% of cases. [60] [61] [62] [63] [64] The risk of subsequently converting to clinically definite MS varies for different ethnic and geographic populations. In Western Europe and the United States, over half of patients who present with optic neuritis will have lesions identified on MRI suggestive of MS (borne out in the ONTT where ultimately 75% of patients were diagnosed with clinically definite MS within 15 years if they had an abnormal MRI at presentation). In contrast, in Japan only 14% of patients with optic neuritis are found to have lesions on MRI suspicious for MS. 5, 65 Appropriate initiation of long-term disease-modifying therapy must account for this ethnic and geographic variation in trying to calculate risk of developing MS in an individual patient. The following discussion will focus mostly on the available data from studies of European and North American populations.
Given that many patients presenting with optic neuritis will have no future neurological relapses, there is an imperative need for robust clinical biomarkers at first clinical presentation to help guide the decision to initiate long-term immunomodulatory treatment. The most robust predictor of possible progression to clinically definite MS remains MRI of the brain and spinal cord. Other ancillary tests such as the presence of oligoclonal bands in the CSF have modest predictive value and VEP or OCT may reveal underlying asymptomatic optic neuropathy, which could also hint at prior episodes of demyelination. 42 To date, there have been 6 randomized controlled trials that investigated the impact of MS medications on the risk of conversion from high-risk clinically isolated syndrome (an acute demyelinating event with lesions on brain MRI typical of MS) to clinically definite MS. These studies, which used interferons, glatiramer acetate, and teriflunomide as treatment after an initial demyelinating event, showed a reduction in developing MS of 28-45% over the subsequent 2-3-year follow-up period, reduction in accrual of lesions detected on brain MRI, and decrease in brain atrophy. [66] [67] [68] [69] [70] [71] [72] However, these studies did not demonstrate any improvement in long-term disability. Nevertheless, starting treatment early and decreasing the number of early relapses theoretically may decrease the severity of the natural history of MS, and population studies have shown prolongation of disability-free survival. 73, 74 Along these lines, several studies have shown that decreasing lesion burden on MRI delays or prevents secondary progressive MS and that 75% of patients with an elevated lesion volume on MRI early in the disease course will advance to an Expanded Disability Status Scale worse than 6 within 5 years. 75, 76 Although the lack of clinical trial data definitively showing improvement in long-term disability is disheartening, the MS medications that are considered more potent (ie, natalizumab) have not been studied at the time of initial presentation with a clinically isolated syndrome. These treatments could arguably have more robust results but conversely can have more deleterious adverse effects.
It is our routine practice to discuss starting an MS medication with patients presenting with optic neuritis that have an MRI showing lesions suggesting a high risk of conversion to clinically definite MS; however, this practice is not uniform across the world. The Optic Neuritis Survey Group demonstrated how varied practice is among different communities-99% of neurologists in the United States would recommend starting an MS medication to patients with an abnormal MRI and optic neuritis, whereas only 53% of neurologists would recommend the same in Thailand. This discrepancy reflects the overall prevalence of MS in these populations. In addition, some providers recommend disease-modifying agents for MS in patients with isolated optic neuritis and a normal brain MRI, although current evidence does not support this practice. 20 
CONCLUSIONS
To a large degree, the approach to the treatment of optic neuritis and the decision to use corticosteroids still relies heavily on results from the ONTT. However, with several new exciting therapies currently in phase 2 and phase 3 trials, we are hopeful that we will soon see a more targeted approach to the treatment of optic neuritis and further improvement in patient outcomes. We anticipate that treatment options for optic neuritis will continue to evolve, encompassing immunosuppressive, neuroprotective, and possibly remyelinative strategies.
